#7/I.D.S.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: KATO=21

In re Application of:

Art Unit: 1641

Yukio KATO et al.

Examiner:

Appln. No.: 10/049,957

Confirmation No. 8967

Filed: February 19, 2002

Washington, D.C.

For: CHONDROGENESIS PROMOTERS

April 29, 2003

RECEIVED

INFORMATION DISCLOSURE STATEMENT [IDS]

APR 3 0 2003

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

APR 2 9 2003

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above- identified application, and any other application relying on the filing date of the above-identified application or cross- referencing it as a related application.

- This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.
- In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an

In re Appln. No. 10/049,957

attachment hereto. A copy of each document listed is attached.

- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. In accordance with 37 CFR §\$1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in \$1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

Bv:

y M. Finkelstein eg. No. 21,082

JMF:btd

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

G:\BN\Y\YUAS\Kato21\PTO\IDS apr03.doc

Substitute for form 1449A/PTO	Co	Complete if Known	
	Application Number	10/049,957	
INFORMATION DISCLOSURE	Filing Date	February 19, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Yukio KATO et al.	
	Group Art Unit	1641	
(use as many sheets as necessary)	Examiner Name	71	
Sheet 1 of 1	Attorney Docket Number	KATO=21 TECLIO	
		ECH CE	
OTHER PRIOR ART - NON	N PATENT LITERATURE D	OCUMENTS	
itials* Include name of the author (in CAF	PITAL LETTERS), title of article (wi symposium, catalog, etc.), date, pa r, city and/or country where publish	ge(s), volume-issue number(s),	
AH HILL et al., "Peptide Growth Factors and The Research, Pergamon Press, GB, vol. 4, no. 1	eir Interactions During Chondro 1, pp. 45-68 (1992)	genesis", <u>Progress in Growth Facto</u>	
1			
Examiner	Date	1	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.